Wednesday, May 23, 2012 2:43:23 AM
NAVB..$2.89..ASCO WATCH..will be presenting sharing solid data at ASCO 2012.
A phase III study of receptor-targeted 99mTc-tilmanocept versus blue dye in the evaluation of SLNs in breast cancer and melanoma.
http://meeting.ascopubs.org/cgi/content/short/29/18_suppl/LBA8526?rss=1
A phase III study of receptor-targeted 99mTc-tilmanocept versus blue dye in the evaluation of SLNs in breast cancer and melanoma.
http://meeting.ascopubs.org/cgi/content/short/29/18_suppl/LBA8526?rss=1
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
